Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by Dude51on Mar 06, 2021 3:40pm

223 Views

Post# 32736870

One more point bashers/shorters, I got to thinking

It's not always what you know but who you know. Here I will state my proof, cause I always like to back up my insinuations with the truth. Right, judging from you spews insinuation is beyond your comprehension, what ever losers this is from Stockwatch:

"Claritas Pharmaceuticals Inc. (formerly Kalytera Therapeutics Inc.) has entered into a strategic collaboration agreement with the Salzman Group Ltd."

Gee I wonder why? Oh, those Barda contracts. Does that come before or after FDA approval?
Beam me up Scotty...

GLTA

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?